05/11/2001
London, UK – 5 November 2001: ReGen Therapeutics Plc (“ReGen” or the “Company”), a company developing a potential treatment for Alzheimer’s disease, announces that at the Extraordinary General Meeting held earlier today regarding the issue of new ordinary shares pursuant to the placing announced on 11 October 2001 (‘Placing’), shareholders unanimously voted in favour of all the proposed resolutions which, inter alia, authorises the directors to allot shares and approves the disapplication of pre-emption rights in relation to the Placing.
The Company has conditionally placed 10,489,627 new ordinary shares at 10p per new ordinary share pursuant to the Placing (“New Ordinary Shares”). The New Ordinary Shares were allotted (subject only to admission to Alternative Investment Market of the London Stock Exchange plc) at a meeting of the committee of the Board held earlier today. Application has been made for the New Ordinary Shares to be admitted to the Alternative Investment Market of the London Stock Exchange plc and dealings are expected to commence at 8.00 am on 6 November 2001.
For further information, please contact:
Lisa Baderoon
BUCHANAN COMMUNICATIONS
lisab@buchanan.uk.com
Tel No: 020 7466 5000
M: 07721 413496